Why carry out this study?

Retinal ischemia, thought to be the mediator in most cases of neovascular glaucoma, results in the release of angiogenic factors, such as vascular endothelial growth factor (VEGF), which trigger neovascularization.

It has been suggested that intravitreal anti-VEGF agents may improve intraocular pressure (IOP) and neovascularization in patients with neovascular glaucoma.

The VEGA study was designed to assess the efficacy and safety of intravitreal aflibercept (IVT-AFL) in patients with neovascular glaucoma.

What was learned from the study?

IVT-AFL was associated with clinically meaningful improvements in IOP control (least squares mean difference of − 4.9 mmHg between IVT-AFL and sham) and neovascularization grades, despite not meeting the primary endpoint.

The incidence of treatment-emergent adverse events was consistent with the known safety profile for IVT-AFL.

IVT-AFL may be a potential treatment option for patients with neovascular glaucoma.